Login / Signup

Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.

Jan-Niklas BeckerRobert HermannJörn WichmannMathias SonnhoffHans ChristiansenFrank Bruns
Published in: PloS one (2023)
LSMM is a predictive factor for DLT in head and neck patients treated with low-dose weekly chemoradiotherapy with cisplatin. For paclitaxel/carboplatin, further research must be carried out.
Keyphrases
  • low dose
  • skeletal muscle
  • rectal cancer
  • locally advanced
  • patients undergoing
  • high dose
  • phase ii study
  • insulin resistance
  • radiation therapy
  • type diabetes
  • clinical trial
  • randomized controlled trial